ALTIMMUNE, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
ALTIMMUNE, INC. (ALT) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of $6.21 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-14.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2017-03-14
- ALTIMMUNE, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2016 was $6.21K, a 10.10% decline from fiscal 2015.
- ALTIMMUNE, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2015 was $6.91K.
- ALTIMMUNE, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2014 was -$6.27K.
- ALTIMMUNE, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2013 was -$2.71M, a 54495.10% decline from fiscal 2012.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month |
|---|---|
| 2016-12-31 | $6.21K 10-K · filed 2017-03-14 |
| 2015-12-31 | $6.91K 10-K · filed 2017-03-14 |
| 2014-12-31 | -$6.27K 10-K · filed 2017-03-14 |
| 2013-12-31 | -$2.71M 10-K · filed 2016-03-11 |
| 2012-12-31 | $4.97K 10-K · filed 2015-03-11 |
| 2011-12-31 | $22.10K 10-K · filed 2014-03-11 |
| 2010-12-31 | $607.98K 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |